2/27
01:12 pm
imnn
Imunon, Inc. (NASDAQ: IMNN) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $29.00 price target on the stock.
Low
Report
Imunon, Inc. (NASDAQ: IMNN) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $29.00 price target on the stock.
2/27
08:05 am
imnn
IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study
Low
Report
IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study
2/26
08:05 am
imnn
IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19
Medium
Report
IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19
2/20
07:17 pm
imnn
IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025 [Yahoo! Finance]
Medium
Report
IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025 [Yahoo! Finance]
2/20
08:30 am
imnn
IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025
Low
Report
IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025
2/19
10:11 am
imnn
Imunon, Inc. (NASDAQ: IMNN) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $29.00 price target on the stock.
Medium
Report
Imunon, Inc. (NASDAQ: IMNN) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $29.00 price target on the stock.
2/19
08:05 am
imnn
IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer
Low
Report
IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer
2/10
08:05 am
imnn
IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer
Low
Report
IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer
2/27
08:16 am
imnn
Form 10-K Imunon, Inc. For: Dec 31
High
Report
Form 10-K Imunon, Inc. For: Dec 31
2/27
08:10 am
imnn
Form 8-K Imunon, Inc. For: Feb 27
High
Report
Form 8-K Imunon, Inc. For: Feb 27
2/19
04:18 pm
imnn
Form 4 Imunon, Inc. For: Feb 18 Filed by: Faller Douglas Vincent
Medium
Report
Form 4 Imunon, Inc. For: Feb 18 Filed by: Faller Douglas Vincent
2/18
04:32 pm
imnn
Form 3 Imunon, Inc. For: Feb 18 Filed by: Faller Douglas Vincent
Low
Report
Form 3 Imunon, Inc. For: Feb 18 Filed by: Faller Douglas Vincent
2/13
01:51 pm
imnn
Form SCHEDULE 13G/A Imunon, Inc. Filed by: Ayrton Capital LLC
Low
Report
Form SCHEDULE 13G/A Imunon, Inc. Filed by: Ayrton Capital LLC
2/10
08:11 am
imnn
Form 8-K Imunon, Inc. For: Feb 09
Low
Report
Form 8-K Imunon, Inc. For: Feb 09
1/28
04:18 pm
imnn
Form 4 Imunon, Inc. For: Aug 20 Filed by: Braun Donald P
Low
Report
Form 4 Imunon, Inc. For: Aug 20 Filed by: Braun Donald P
12/19
04:15 pm
imnn
Form 4 Imunon, Inc. For: Dec 18 Filed by: Tardugno Michael H
High
Report
Form 4 Imunon, Inc. For: Dec 18 Filed by: Tardugno Michael H
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Order Stats
Sub-Penny
Odd lot
Avg. bid-ask spread
Avg. bid-ask size
Shares at ask/bid
Off exchange
Main News & Impact Reports
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Register